Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

WHY? Interesting.
Outstanding Shares 131,320,668 a/o Apr 05, 2017
http://www.otcmarkets.com/stock/CTIX/profile

FROM TODAY's 10-Q
The number of shares outstanding of each of the issuer’s classes of common equity, as of May 1, 2017 is as follows:
131,380,668


So in 1 month Leo added only 60,000 shares!!!! Huh??? Based on all the DOOM AND GLOOMers here - ASPIRE just unloaded on us? LOL
Or no - it was ARUDA.....lol - - not true either as he released his SC 13 G/A the other day. CTIX is running a TIGHT ship.


CASH ON HAND - 5.7 Million - PLENTY!!!!
We still have 16 MILLION from ASPIRE - PLENTY!!!!


P - Between the subjects already enrolled and those presently in screening, we have reached approximately 70% of the anticipated subjects. Subject recruitment was slower than projected due to competitive trials. In response, we have added additional investigator sites. The Company expects interim analysis top-line results in the third quarter of calendar 2017. Cellceutix’s expenditures on Prurisol were approximately $1.1 million and $2.7 million during the three months and nine months ended March 31, 2017

K - Toxicology studies for the oral formulation of Kevetrin began January 2017. Cellceutix’s expenditures on Kevetrin were approximately $0.4 million and $0.7 million during the three months and nine months ended March 31, 2017, respectively.

B - Completion of the trials and reporting of results from the Phase 2 P-o-C clinical trial of Brilacidin-UP/UPS and Phase 2 of Brilacidin -OM are anticipated over the coming months.
B-ABSSSI - Our strategy for now is to achieve success with other trials and attract partnering opportunities with significant down payments and milestone payments which can fund these trials.
Cellceutix’s expenditures on Brilacidin were approximately $0.5 million and $1.3 million during the three months and nine months ended March 31, 2017, respectively.

We spent 300K less on clinical trials this year.

NICE JOB CTIX!!!!


Our strategy for now is to achieve success with other trials and attract partnering opportunities with significant down payments and milestone payments which can fund these trials.